Health Department Faces Scrutiny Over TB Drug Shortage in Government Hospitals
Three-Month Disruption in TB Medicine Supply
Government hospitals are facing a prolonged shortage of tuberculosis (TB) medicines, with supplies reportedly unavailable for the past three months. The disruption has affected treatment continuity across multiple facilities, raising concerns among healthcare workers and patients.
Tuberculosis, a critical public health concern, requires uninterrupted medication to ensure recovery and prevent drug resistance. The absence of essential drugs has left patients dependent on inconsistent alternatives or forced them to seek costly private care.
Around 70,000 Patients Affected
The shortage is estimated to have impacted nearly 70,000 TB patients. Many of them rely exclusively on government healthcare systems for free diagnosis and treatment under national TB control programmes.
Patients undergoing long-term therapy are among the worst affected. Interruptions in medication cycles can lead to severe complications, including relapse and increased risk of transmission within communities.
Pressure Mounts on Public Health System
The situation has brought renewed attention to gaps in the public health supply chain. Government hospitals, which cater to economically vulnerable populations, are struggling to manage patient loads without adequate drug availability.
Healthcare workers have reported growing distress among patients, many of whom are unable to afford treatment outside the public system. The lack of clarity on when supplies will be restored has added to the uncertainty.
https://x.com/BRSparty/status/2046099204125364489?s=20
Need for Immediate Administrative Intervention
Public health experts have consistently stressed that uninterrupted drug supply is central to TB elimination efforts. Any delay in procurement or distribution directly undermines ongoing national health initiatives.
Authorities are expected to address the issue through urgent intervention to restore supply chains and prevent further disruption. Ensuring consistent availability of TB medicines remains critical to safeguarding patient outcomes and controlling the spread of the disease.